OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally chan

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Iambic. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other o

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture-philanthropy organization dedicated to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today celebrated the closing of a US$37 million Series A financing by portfolio company Altay Therapeutics, Inc. The financing was co-led by Sound Bioventures and HealthCap, with participation from Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund. Altay intends to use the pr

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces CE marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers

LEMONT, Ill.--(BUSINESS WIRE)--In a result published in Physical Review Letters, scientists build a link with a spin wave, advancing new functions in hybrid quantum systems.

CANTON, Ohio--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading nonprofit breast cancer organization, today joined Rep. Emilia Sykes, Northeast Ohio breast cancer advocates and Cleveland Clinic Mercy Hospital Cancer Center leaders for a community roundtable focused on improving access to timely breast cancer imaging for patients across Ohio. More than 11,000 people in Ohio will be diagnosed with breast cancer in 2026 and more than 1,500 will die from the disease this year alone.The roundtabl

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) to include patients with BCG-unresponsive NMIBC with papillary-only tumors. The expanded FDA label reads as follows: ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG), is in

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed o

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, will announce financial results for the quarter ended September 30, 2026 on Monday, October 26, 2026, before market open. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Offic

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time. Conference Call and Webcast What:   OmniAb conf

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4849 or 1-203-518-9848 and reference Marav

BIRMINGHAM, Ala.--(BUSINESS WIRE)--8 Bridge Group, LLC (“8 Bridge Group”) today announced its strategic investment and acquisition of a majority stake in 340BIntel, LLC (“340BIntel”), marking the firm’s expansion into the healthcare technology sector. The investment represents the first phase of a long-term initiative expected to exceed $2 billion in revenue over the next decade, supporting innovative software solutions that strengthen healthcare operations and improve financial sustainability f

COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle and CMC Pharmaceuticals are advancing work with the United States Department of War to develop improved medical countermeasures intended to protect American warfighters from nerve agent threats. The five-year, $40 million Acetylcholinesterase (AChE) Reactivator Development and Approval Pipeline (ARDAP) Prototype Program was awarded through the Defense Threat Reduction Agency, Joint Science and Technology Office (DTRA-JSTO). The program is focused on adv

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--MED Institute has joined Novelna Inc. and its consortium partners on Proactive Unified Longitudinal Sensing Ecosystem (PULSE), a wearable biosensing platform selected by the Advanced Research Projects Agency for Health (ARPA-H) under its Delphi program. MED Institute will support PULSE with in vivo biosensor testing, regulatory support, and clinical study services.Through PULSE, Novelna and its consortium partners will develop a wearable biosensing platform

CHICAGO--(BUSINESS WIRE)--Portal Innovations today announced the release of Biotech’s Next Frontier: Emerging Hubs Built for Efficiency and Outsized Returns, a new analysis developed by its venture team examining a decade of financing, clinical development, and exit data across the U.S. biotechnology industry. Drawing on data covering more than 11,000 life sciences companies and nearly 30,000 financing deals from 2015 through 2025, the analysis compares established biotech hubs in California an

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME eligible, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that eyonis Inc., its U.S. subsidiary, will participate in the CHEST 2

NASHVILLE, Tenn.--(BUSINESS WIRE)--Cyted Health today announced positive clinical validation data from DETECT-ME, a prospective, multicenter study of the EndoSign® Barrett’s Esophagus (BE) Test. Conducted at 18 U.S. clinical sites, the study compared Cyted’s non-endoscopic, methylation-based test directly against standard endoscopy and biopsy, using samples collected with the FDA 510(k)-cleared EndoSign® Cell Collection Device. The data was presented at the American College of Gastroenterology

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in Nature that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center, the team discovered new insights that challenge long-held assumptions of the fundamental chemistry of lithium-ion batteries, including multi-lithium ion complexes that may

SAN MATEO, Calif.--(BUSINESS WIRE)--Baszucki Group funds UAB Montgomery clinical study to examine impact of ketogenic therapy on people living with bipolar disorder in rural Alabama

BEVERLY HILLS, Calif.--(BUSINESS WIRE)-- #CarlosVela--Carlos Vela and Saioa Cañibano join Evoria Health as partners, bringing a shared commitment to daily nutrition, longevity and recovery.

DALLAS--(BUSINESS WIRE)--Verily Health Inc., a healthcare data intelligence company, announced today that it has been awarded a contract by the Centers for Disease Control and Prevention (CDC) to continue supporting the national wastewater-based infectious disease surveillance program, building on the work that the company has performed for the CDC since 2023. Under the new award, Verily Health will support CDC's National Wastewater Surveillance System through Verily Sightline, combining wastew

WALTHAM, Mass.--(BUSINESS WIRE)--Dash Bio, the company building the infrastructure that drug development needs for the next generation of medicines, today announced it has been named to the AI Disruptors 60 Class of 2026. The annual list recognizes 60 of the world's most groundbreaking AI startups. Curated by Greenfield Partners, the Class of 2026 is unveiled today on stage at TechCrunch Disrupt 2026 in San Francisco and is presented on the Nasdaq MarketSite tower in Times Square. The bottlenec

NEW YORK--(BUSINESS WIRE)--Hitchhiker Orbital Inc. (HHO), a space technology firm designing microgravity enclosures, today announced the appointment of Dr. Spencer P. Magleby to its Board of Directors. Dr. Magleby brings over three decades of leadership in mechanical design, compliant mechanisms and deployable space structures. Dr. Magleby is Dean of the Smith College of Engineering and Technology at Utah Valley University (UVU) and Professor Emeritus of Mechanical Engineering at Brigham Young

HOUSTON--(BUSINESS WIRE)-- #bioeconomy--Cemvita, an emerging frontier AI lab for industrial BioSolutions, today announced a partnership with Roebling, an AI-native engineering firm, to speed the discovery, evaluation and deployment of biological solutions for the natural-resource industries.Cemvita brings more than a decade of experience developing and scaling industrial biotechnology, along with proprietary biological, fermentation, process and deployment data. Through its BioSolutions Discovery Platform, th

ROCKVILLE, Md.--(BUSINESS WIRE)--National Institutes of Health Director Jayanta “Jay” Bhattacharya, M.D., Ph.D., former Food & Drug Administration leaders Julie Tierney and Tala Fakhouri Ph.D. M.P.H., and investigative journalist and Bad Blood author John Carreyrou will serve as keynote speakers at the Maryland Tech Council’s Bio Innovation Conference on Friday, October 23, 2026. Attendees will gain insights from national and industry leaders on the issues shaping the future of life science

CLARKSBURG, Md.--(BUSINESS WIRE)--For the last 53 years, BrightFocus Foundation, a nonprofit dedicated to Alzheimer’s, macular degeneration, and glaucoma research, has been making an unconventional bet. What happens when you give promising and emerging scientists funding to pursue early‑stage, high‑risk research that could lead to major scientific advances and future competitive grants? According to an impact assessment commissioned by BrightFocus and conducted by the American Institute of Biol

FOUNTAIN VALLEY, Calif.--(BUSINESS WIRE)-- #dogDNA--Now with over 25 behavioral insights, the world's leading pet DNA test delivers science-backed data to provide more ways to understand dogs.

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™ launches Qare™, a comparative health platform for users to benchmark self-reported GLP-1 treatment experiences by cohort.

MINNEAPOLIS--(BUSINESS WIRE)--Pivot Bio’s Chief Technology Officer Travis Frey, Ph.D., brought the science behind biological nitrogen to the TEDxFargo stage with the recent video release of his new talk, The Smallest Factory in the World, exploring how advances in microbial technology are creating new possibilities for how agriculture produces and delivers nitrogen. Frey is no stranger to the science behind how crops work best, with more than 20 years of experience working in crop science. Wide

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the

ITASCA, Ill.--(BUSINESS WIRE)--Gryphon Investors' portfolio company Vivify Specialty Ingredients ("Vivify" or the “Company”), a leading provider of specialty colorants, additives, and ingredients for the food & beverage, personal care & cosmetics, and industrial end markets, announced today that it has acquired AuNutra Industries (“AuNutra”), a supplier of botanical extracts and specialty nutritional ingredients to the nutraceutical and supplement industries. Financial terms of the trans

MINNEAPOLIS--(BUSINESS WIRE)--Visana's expanded weight care model integrates hormonal, metabolic and lifestyle interventions to improve health outcomes and better manage costs.

ROSEMONT, Ill.--(BUSINESS WIRE)-- #Antibodies--Proteintech Group, Inc. (the “Company” or “Proteintech”), a global life sciences company, today announced the appointment of Patrick Yount as Chief Financial Officer, effective October 26, 2026, and the promotion of Jeb Gaybrick to Vice President of Corporate Strategy and Investor Relations. These appointments strengthen the Company’s leadership team as it continues its next phase of growth. As Chief Financial Officer, Yount will serve as a strategic and operati

NEW YORK--(BUSINESS WIRE)--ROSE is an exposure health company focused on helping people better understand and reduce the invisible contaminants in their homes. Today, the company officially launches with its first product, The Water Test, a comprehensive home solution that analyzes a single tap-water sample in an ISO-certified lab for more than 100 contaminants, including PFAS, commonly known as “forever chemicals.” Developed over a year of R&D with ROSE’s team of scientists, the test pairs

NEW DELHI & NEW YORK--(BUSINESS WIRE)--Marsh (NYSE: MRSH), a leading global professional services firm, and Bloomberg New Economy today announced the launch of their Competitive Resilience Coalition, a new initiative bringing together private and public sector leaders to help businesses and economies anticipate and manage risk and drive growth through periods of seismic change. The Coalition will provide practical guidance and frameworks that help leaders navigate the world’s greatest challenge

SEATTLE--(BUSINESS WIRE)-- #BioTech--Curi Bio Expands the Curiverse™ with New Disease Models, Casting Kits, and Application-Ready Solutions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA (siRNA) program for the treatment of myotonic dystrophy type 1 (DM1), can directly reduce pathogenic DMPK transcripts within the nucleus, where the molecular drivers o

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein engineering, its pr

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has entered into an option agreement with a privately held company developing a novel, procedure-based, sustained-release injectable treatment for hair restoration.The agreement advances Evolus’ business development strategy by adding a potential new category that is complementary to its existing injec

NASHVILLE, Tenn.--(BUSINESS WIRE)-- #Cryomate--Cryomate Sperm Bank opens its second U.S. location in Nashville, expanding access to diverse sperm donors backed by advanced genetic screening.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) resubmission for tabelecleucel,

BOSTON--(BUSINESS WIRE)-- #IDweek--Delve Detect Plasma enables unbiased detection of more than 68,000 bacteria, fungi, DNA and RNA viruses, and parasites with next-day results

DUBLIN--(BUSINESS WIRE)-- #CardiovascularHealth--B-Secur and Beacon Hospital Research Institute launch clinical pilot to bring ECG data from any consumer wearable directly into the clinical workflow.

BOSTON--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company’s pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Ther

DOVER, Del. & EPALINGES, Switzerland--(BUSINESS WIRE)--Pilatus Biosciences Announces First Patient Dosed in Hong Kong Clinical Trial of PLT012 for Liver Cancer Expansion

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- #Biopharma--Global CRO Worldwide Clinical Trials is named a 2026 SCRS Eagle Award finalist, recognized for strong partnerships with clinical research sites.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shenandoah Therapeutics Appoints Steve Worland, Ph.D., as Chief Executive Officer

LONDON & BERKELEY, Calif.--(BUSINESS WIRE)--Bactobio and the DOE Joint Genome Institute are building a dataset linking bacterial genes to molecules, to power AI discovery of new antimicrobials.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ironfist Therapeutics (“Ironfist”), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor-associated macrophages without a targeting ligand, will present positive preclinical proof-of-concept results for 177Lu-Tamrada at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM’26), taking place October 17–21, 2026, in Vienna, Austria. In an orthotopic syngeneic model of pancr

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced that it has completed enrollment of the Phase 1b FORTRESS study of NG-350A, an oncolytic immunotherapy for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC). The FORTRESS study enrolled 33 participants with pMMR LARC across seven sites in the United States and the United Kingdom to evaluate the effic

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).Coya plans to initiate the OLE in response to requests from ALSTARS inves

TRUTH OR CONSEQUENCES, N.M.--(BUSINESS WIRE)--Virgin Galactic (NYSE: SPCE), a leader in commercial spaceflight and advanced aerospace technology, today announced a Cooperative Research and Development Agreement (CRADA) with the Air Force Research Laboratory's (AFRL) Space Warfare Directorate at Kirtland Air Force Base, New Mexico — the Department of the Air Force's primary organization for space environment research and technology development. The 24-month agreement will explore the use of Virg

PISCATAWAY, N.J.--(BUSINESS WIRE)-- #ageverification--The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, pare

SAN CARLOS, Calif.--(BUSINESS WIRE)--Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer’s disease and other tauopathies. These results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company’s internally developed interleukin-13 (IL-13) and interleukin-31 (IL-31)Rα bispecific antibody, will be shared for the first time at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16, 2026, in Phoenix, AZ. “Atopic dermatitis and other IL-13- and I

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #engineering--eGenesis to Participate in the Virtual U.S. Bancorp | BTIG Kidney Health Forum with Panel Discussion and Investor Meetings

TORONTO--(BUSINESS WIRE)-- #brainhealth--Muse today announced Muse Brain Age, a weekly measure of how old a person's brain appears relative to their actual age. It is the only consumer brain age measure derived from direct brain activity, developed from peer-reviewed research published in Imaging Neuroscience. Muse Brain Age begins rolling out in the Muse app for iOS and Android on October 19 on Muse 2, Muse S and Muse S Athena, and every user's first reading is free. In the Alzheimer's Association's 2026 Fac

LOS ANGELES--(BUSINESS WIRE)--Pelage Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class regenerative treatments for hair loss, today announced that the first patient has been dosed in the Phase 2/3 AWAKEN clinical trial evaluating PP405 in adult men with androgenetic alopecia (AGA), also known as pattern hair loss. The trial initiated on schedule following a positive end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA).“Dosing the first pa

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases. “At Pfizer, we address some of the most urgent challenges i

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and communities impacted by TRD. The campaign is being amplified by leading mental health organizations, including National Alliance on Mental Illness (NAMI), Mental Health

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 312,503 shares of its

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. Mr. Bailey will also continue to serve on the Company’s Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and cont

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Come visit Rockwell Medical in Booth #1049 at ASN Kidney Week 2026 at the Colorado Convention Center in Denver, CO.

OSHKOSH, Wis.--(BUSINESS WIRE)--Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK] business, today announced a partnership with Michigan Technological University’s Advanced Power Systems Research Center (APS LABS) to support the technology transition of a Vehicle Integrated Power Kit (VIPK).The VIPK is designed to deliver mobile, on-platform energy to support critical battlefield operations, including a wide range of Counter Unmanned Aircraft Systems (C-UAS), directed energy weapon systems,

Oxford, UK, and San Francisco, CA--(BUSINESS WIRE)-- #ChemicalManufacturing--Biomanufacturing startup HydRegen makes chemical manufacturing greener and up to 40% more cost-effective by replacing metal catalysts with enzymes.

HOFFMAN ESTATES, Ill.--(BUSINESS WIRE)--Otometrics, the Hearing & Balance division of Natus Sensory, today announced Aurical® IQ, the next generation of its trusted hearing aid fitting and verification platform. Combining the first and only Guided Workflow for hearing aid fitting and verification, support for the NAL-NL3 Fitting System and a redesigned Otosuite® software experience, Aurical IQ is designed to help hearing care professionals work more efficiently and follow best-practice fitt

ZUG, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone Tactical Opportunities (“Blackstone”) and the Obagi family. Founded by dermatologist Dr. Zein Obagi and headquartered in Irvine, California, ZO Skin Health has been a reference name in cl

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to

MIAMI & BALTIMORE--(BUSINESS WIRE)-- #ClinicalAI--OpenEvidence and Johns Hopkins Medicine are collaborating to design medical education and clinical care for the AI era, with patients at the center.

WALTHAM, Mass.--(BUSINESS WIRE)-- #ACR2026--Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026.

NEW CASTLE, Del. & SAN ANTONIO--(BUSINESS WIRE)--IgniteData, a leader in intelligent clinical trial data automation, and RealTime eClinical Solutions, a leader in clinical research software solutions, today announced a new partnership which will provide RealTime’s network of clinical research sites with expanded access to IgniteData’s Archer platform to securely and efficiently transfer clinical data. Archer is the only platform built from the ground up solely to solve for long-standing data tr

WHITMORE LAKE, Mich. & SARASOTA, Fla.--(BUSINESS WIRE)--Trace Medical, a national leader in advanced respiratory rentals and biomedical services, announced that it has acquired a majority interest in LiViliti Health Products, Inc. The acquisition follows LiViliti receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Paptizer 360 classified as a Class II Respiratory Accessory Microbial Reduction Device for CPAP equipment. The majority acquisition builds upon the exi

TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, and Mantra™, a consumer health company developing single-serve, over the counter (OTC) oral gel products for everyday relief, today announced a commercial supply agreement for Mantra’s oral gel product platform. Catalent will provide formulation development, commercial manufacturing and pa

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2026 were $7.82 million compared to $7.83 million for the third quarter of fiscal 2025. Net Income The Company reported net income of $1.27 mil

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new drug application amendment to the U.S. Food and Drug Administration to study its lead candidate, ST-100 (vezocolmitide), in corneal wound healing. The planned proof-of-concept study would mark ST-100's first expansion beyond dry eye disease and co

BOCA RATON, Fla.--(BUSINESS WIRE)-- #LumbarDecompression--SurGenTec®, a privately held medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that it has entered into an exclusive license agreement with Allevion Medical for its patented Vantage™ spinal decompression technology. Under the terms of the agreement, SurGenTec® has secured exclusive rights to Allevion Medical's Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally in

DENVER--(BUSINESS WIRE)-- #AI--Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly's TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular ima

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced the completion of its first flight hardware manufactured under a production agreement with Italian engineering company Robby Moto Engineering S.R.L. ("RME"), marking an important milestone in the Company's continued development of its previously ann

LAUSANNE, Switzerland, WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the healthy aging ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted an ex parte temporary restraining order against the operators of a network of websites that impersonate Timeline’s official site, www.timeli

LAKELAND, Fla.--(BUSINESS WIRE)--As Publix celebrates National Seafood Month, the company continues its long-standing commitment to advancing sustainable seafood by donating nearly $100,000 to Sustainable Fisheries Partnership (SFP) in 2026 alone, bringing its total contribution to the organization to more than $1.2 million.Now in its 16th year, Publix’s collaboration with the nonprofit highlights the company’s environmental stewardship and responsible sourcing efforts. SFP works with the seafoo

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at

MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Juan R. Sanchez-Ramos, M.D., Ph.D., to its Scientific Advisory Board. A neurologist and clinician-scientist whose career has spanned addiction, movement disorders, and neurodegenerative diseases, Dr. Sanchez-Ramos was an early leader in the clinical investigation of ibogaine and a scientific collaborator of DemeRx founder and CEO D

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.

MELBOURNE, Fla.--(BUSINESS WIRE)--Smart seating company Kalogon names former Meta, Magic Leap executive Marty Evans as its first chief technology officer.

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the U.S. launch of an accelerated gene-to-drug substance program for complex biologics, designed to help developers move bispecifics, multispecifics and other next-generation molecules from gene sequence to drug substance in 10 months. The program builds on Catalent's Rapid Antibody offering for t

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi

ANTALYA, Turkey & JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced it has been awarded a contract by Axiom Space, a leader in next-generation space infrastructure, to develop and deliver two Roll-Out Solar Array (ROSA) wings for Axiom Station’s second space station module. As previously announced, Redwire is also building the ROSA wings for Axiom Space’s first space station module. “We are excited an

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer

ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical Announces FDA Clearance of NanoACTIV™ Surface Technology for Its Riva® Posterior Fixation System.

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., an agentic AI and real-world data company advancing oncology drug development and access, today announced its inclusion in TIME’s World’s Top HealthTech Companies 2026 in the AI & Data Analytics category. Produced in collaboration with Statista, the list recognizes 500 companies worldwide based on financial performance, reputation and online engagement. The recognition comes as Massive Bio expands its role as oncology data and AI infrast

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA will join ACIC Pharmaceuticals at CPHI Milan 2026, bringing together ACIC's pharmaceutical expertise and global network of technology partners to showcase an integrated approach to pharmaceutical development, manufacturing and commercialization. From October 6–8, 2026, visitors to Stand 7G106 can meet both teams and discover how ACIC connects pharmaceutical expertise, advanced manufacturing technologies and specialized engineering to help

BOCA RATON, Fla. & COLUMBUS, Ohio--(BUSINESS WIRE)--The TECPR2 Research Foundation, a nonprofit organization established to advance research and development of a treatment for patients with TECPR2, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to advance an AAV gene therapy for patients with TECPR2, an ultra-rare neurodegenerative genetic disease. Under the partners

GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp. today announced that its Co-Founder & Chief Scientific Officer, Dr. David Vaillancourt, will serve as a key scientific leader in a $22 million National Institutes of Health grant supporting the University of Florida-led Alzheimer’s Disease Research Center (1Florida ADRC). The award positions Florida among a select national network of only 37 ADRCs in the United States and the only one located in the state, expanding the region's role in a

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluat

MIAMI & NUREMBERG, Germany--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer risk detection technology, today announced the commercial launch of DermaSensor in Germany through a distribution agreement with ContraCare GmbH. The launch represents a significant milestone in DermaSensor’s international expansion following its recent Class IIb CE Mark under the European Union Medical Device Regulation (MDR) and collaboration with the National Health Service (NHS) in the United K

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela. Unveiled at the annual ASTRO conference, Accela is the first software-driven delivery system engineered for NeoArc (Dynamic Modulated Arc Therapy, DMAT), a new treatment technique that accelerates how radia

MIAMI-DADE, Fla. & BROWARD, Fla. & PALM BEACH, Fla. & DUVAL, Fla. & HILLSBOROUGH, Fla.--(BUSINESS WIRE)--Little more than half (52%) of respondents, and less than half (43%) of those aged 30-39, are very aware that breast cancer diagnoses have been rising among younger patients, according to a poll of more than 1,000 Florida-based women. Findings show 32% are somewhat aware of this increase, and 17% are either not very aware (11%) or not at all aware (6%). Conducted by the TopLine MD Alliance —

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, will bring next-generation innovations for next-level confidence to the ASTRO 2026 Annual Meeting, beginning Sunday, September 27, in Boston. At Booth 915, attendees will get a first look at new solutions for radiation therapy quality assurance (QA), alongside dedicated programming on smarter QA workflows and one of oncology's fastest-growing areas: radiopharmaceutical therapy.An Exclusive Look: A New Way to See Machine Hea

EDISON, N.J.--(BUSINESS WIRE)-- #CollaborativeSurgicalIntelligence--Redefine Surgery, a medical technology company building physical AI for surgery, today announced the closing of an oversubscribed pre-seed financing round, bringing total capital raised to $10 million. Backed predominantly by surgeon investors, the financing will support continued development of the company’s surgical intelligence platform as it advances toward commercialization. The financing announcement follows Wednesday’s announcement by Catalyst OrthoScience

MIAMI & COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading full-stack quantum platform and foundry, today announced a contract with Florida International University (FIU), Miami’s top ranked state university. Under the agreement, IonQ will deliver its Superion 256-qubit trapped-ion quantum computer for installation at FIU.This contract establishes FIU as IonQ’s flagship academic partner in Florida, creating a central hub for quantum research and education across the regio

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Together with more than 20,000 Associates nationwide, AutoNation, Inc. (NYSE:AN) celebrates a decade of DRV PNK and more than $50 million raised and donated to drive out cancer. To commemorate these milestones, AutoNation announced an additional $1 million investment through 10 grants of $100,000 each to 10 longtime partners advancing cancer research and supporting patients, survivors, and caregivers. Over the past decade, DRV PNK has evolved into a defin

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience, Inc. ("Catalyst"), a private medical technology company elevating shoulder arthroplasty through surgeon-focused innovation, today announced it has become the founding partner for shoulder with Redefine Surgery. Building on Catalyst’s leadership in efficient, outcomes-focused shoulder replacement, the partnership expands Catalyst’s role in shaping how shoulder replacement is measured, optimized and continuously improved, unlocking new levels

TAMPA, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--ApalyRx, the pharmacy technology platform that assesses every prescription in real time and routes it to its lowest-cost fulfillment channel on benefit, today announced a partnership with Vida Health, a leading digital health company delivering integrated, longitudinal cardiometabolic and behavioral health care. Together, ApalyRx and Vida Health are enabling self-funded employers to provide plan members with comprehensive clinical weight-loss care a

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx, a leading provider of long-term care, specialty, and infusion pharmacy solutions, has once again been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service, available for the 2026-2027 flu season. This marks the second consecutive year Polaris Rx has earned this exclusive distinction. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home without a doc

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA Inc. is pleased to announce the appointment of Patrice Pelletier as President. In this role, Patrice will lead ACIC Equipment's sales strategy and commercial execution across North America, while also driving the strategic development of a new US facility for the company. Patrice brings more than 20 years of executive leadership experience across industrial technology, infrastructure, and energy transition, with a track record of scaling

ORLANDO, Fla.--(BUSINESS WIRE)-- #InterbodyFusion--Xenix Medical Announces FDA Clearance of the Riva® Anchor Spinopelvic Fixation System with NanoACTIV™ Surface Technology

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) which takes place October 23–27, 2026, in Madrid, Spain. The presentation will take place on Sunday, O

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon (DEB) for the treatment of coronary in-stent restenosis (ISR), marking a major milestone in expanding treatment options for one of the most complex challenges in interventional cardiology. Physicians now have immediate access to the

BOCA RATON, Fla.--(BUSINESS WIRE)--US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and build partnerships across the country's oncology sector. Massive Bio provides an AI-powered platform that connects cancer patients with suitable clinical trials. The company works with global pharmaceutical companies, hospitals and oncologists to identify patients who meet the often highly specific requirements

MIAMI & PHILADELPHIA--(BUSINESS WIRE)--OpenEvidence, the most widely used medical AI and clinical decision-making tool among U.S. physicians, and Penn Medicine today announced a global partnership to bring AI-powered clinical decision support to Penn Medicine's more than 10,000 clinicians across its seven-hospital U.S. health system. That clinical decision support will also extend to low and middle income countries through the Botswana-UPenn Partnership (BUP). Building on Penn Medicine’s deep c

AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2B395--A2 Biotherapeutics to Announce Findings from DENALI-1 Study of A2B395 at 2026 Cell Coast Conference

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing a new class of therapeutics designed to repair helical collagen for the treatment of eye diseases, today announced that Eric Schlumpf, President and CEO of Stuart Therapeutics, will participate in a fireside chat discussion at the Citizens Private Ophthalmology Summit on Thursday, September 17, 2026, at 2 p.m. EDT. The Summit will showcase innovation in ophthalmology with prese

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. As Summit previously announced on July 22, 2026, ivonescimab plus plat

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Perdoceo Education Corporation Signs Definitive Agreement to Acquire South University

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #KnowLpa--The Family Heart Foundation, a leading research, education and advocacy organization, today announced the publication of a new peer-reviewed study in JACC: Advances demonstrating how its FIND Lp(a)® Machine Learning Model can identify people with atherosclerotic cardiovascular disease (ASCVD) who are more likely to have high lipoprotein(a) — or Lp(a). The model has already been successfully deployed at five large U.S. healthcare systems participating in

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. The HARMON

MIAMI & OTTAWA, Ontario--(BUSINESS WIRE)-- #Canada--OpenEvidence and the Medical Identification Number for Canada Corporation (MINC#NIMC) today announced a partnership to streamline physician verification for Canada and support continued free access for verified Canadian clinicians. Medical knowledge keeps accelerating, and clinicians do not have time to chase down answers across dozens of tabs and paywalls. This partnership reduces friction at the moment of sign-up by allowing Canadian physicians to ver

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced positive interim results from its ongoing randomized, double-blind, placebo-controlled Phase 1b study of BEL512, an investigational long-acting bispecific antibody targeting thymic stromal lymphopoietin (“TSLP”) and interleukin-13 (“IL-13”), in patients with mild-moderate asthma. Phase 1b Tr

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., a global leader in AI-driven precision oncology and clinical trial matching, and PrecisCa, an oncology practice support platform offering evidence-based treatment guidance, clinical trial matching, patient communications, and expert second opinions, today announced a strategic partnership to expand cancer patient access to clinical trials across the United States. Under the agreement, Massive Bio will provide concierge support, reporting, an

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that it has entered into a settlement agreement with Shoulder Innovations, Inc. (“Shoulder Innovations”) to resolve all pending patent litigation between the two companies. The agreement resolves the dispute in its entirety. The terms of the settlement agreement are confidential. “Inte

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the space company operating the world’s only commercial fleet of flight-ready Mach 2+ supersonic aircraft, and Vaya Defense & Space, Inc. (“Vaya”), a privately held developer of the patented Vortex-Hybrid rocket engine, today announced entering into a memorandum of understanding (MOU) to explore collaboration on supersonic captive-carry flight testing and air-launch

MIAMI--(BUSINESS WIRE)--Lotus Neuro, a clinical-stage biotechnology company pairing focused ultrasound with leading therapeutic modalities to treat focal neurologic disease, today announced its public launch. Spun out in December 2025 from Insightec, the global leader in incisionless focused ultrasound, Lotus Neuro is built on a clinically validated platform for precision modulation of the blood-brain barrier (BBB) and is dedicated to solving the delivery problem that has stalled decades of pro

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, announced today the close of a $4M Series B extension, including institutional and strategic investors, alongside the launch of a community investment round on Wefunder. This new community financing has already raised more than $1 million at the same terms as the $4M. This follows the company’s $16M Series B, closed in 2025, and brings the total investment in the company to $48 million. The commu

MIAMI--(BUSINESS WIRE)-- #Glaucoma--Heru announced the U.S. launch of the new PretestPro on its Heru Prime wearable platform. PretestPro runs four pretest exams in just 90 seconds.

ATLANTIC BEACH, Fla.--(BUSINESS WIRE)--nPhase launches nPhase.ai and its agentic SCE, turning raw clinical trial data into submission-ready CDISC outputs 4x faster with 80% fewer resources.

LAKE FOREST, Calif.--(BUSINESS WIRE)--SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy

MONTPELLIER, France & MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will unveil new features for its Epione® robotic platform at the 2026 annual congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Copenhagen, Denmark, September 5–9, on Booth D39. The updated platform will feature new AI capabilities and compatibility with one of the latest-generation angiography systems from GE HealthCare enabling

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. HARMONi-2 (AK112-303) is a single-region, multi-center Phase III study conducted in China

MIAMI--(BUSINESS WIRE)--Over 90 Segal Trials employees have joined CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon, a two-week event combining physical activity and fundraising to recognize the clinical research participants and professionals who make medical progress possible. Running September 1 through September 15, the Appreci-A-Thon raises funds to support CISCRP’s work educating and empowering patients and the public about clinical research. Just two days into the challenge, Segal Trial

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced it has signed a memorandum of understanding (“MOU”) with The Bionetics Corporation (“Bionetics”) to integrate and process a series of pathfinder small payloads for missions aboard the Company’s F-104 aircraft. Under the MOU, Bionetics will work with

MIAMI--(BUSINESS WIRE)-- #DebtJustice--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will co-host a webinar, “Freedom from Debt: A Global Dialogue on Fiscal Space, Health, and Development,” on Thursday, September 3, 2026, at 10:00 AM EDT, virtually via Zoom. Register here. Sovereign debt has emerged as a defining challenge at the intersection of global finance, sustainable development, and public health. Across many low- and middle-income countries,

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ F-104 supersonic aircraft, announced it will participate in the September 12-13 AIRSHO at the Midland International Air & Space Port in Texas, showcasing its historic F-104 aircraft in both flight and static displays. For Starfighters, the event provides a unique opportunity to sho

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, today announced a major expansion of its U.S. commercial strategy through a series of strategic partnerships to accelerate adoption of its FDA cleared, handheld skin cancer detection device across primary care, enterprise healthcare, and federal healthcare systems. The Company's commercial expansion includes 1) an approved supplier relationship with Henry Schein, Inc., the world’s largest provide

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)-- #clinicalai--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company’s investor relations website: https://www.conmed.com/en/inv

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of Dave LeCause as senior commercial advisor. LeCause will lead the company's commercial strategy as Stuart advances its lead therapeutic candidate, ST-100 for dry eye disease. ST-100 is expected to begin Phase 3b clinical trials in the first quarter of 2027. LeCause joins Stu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusi

TAMPA, Fla.--(BUSINESS WIRE)--Catalent has completed a significant debt refinancing transaction to support its future growth while reducing its annual interest expenses.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mu

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates

MIAMI--(BUSINESS WIRE)-- #AI--Arcadia Capital, the premier strategic advisor and investment bank to leaders in the tech and tech services ecosystem, served as exclusive financial advisor to InformedDNA ("IDNA" or "the Company"), a portfolio company of Truehelm and QHP Capital, in the divestiture of its Genetic Testing Utilization Management ("GTUM") business unit to Zyter, a subsidiary of Infinite, a global technology company. The transaction marks the Company's continued investment in and focus on D

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leading provider of cellular-connected remote patient monitoring (RPM) solutions, today called on RPM vendors, healthcare providers, and industry partners to mobilize against provisions in the Centers for Medicare & Medicaid Services' (CMS) proposed Calendar Year 2027 Physician Fee Schedule (PFS) that could sharply curtail access to remote monitoring for millions of Medicare beneficiaries. The proposed rule, issued July 14, 2026, includes several

MINNETONKA, Minn. & REHOVOT, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS), a global leader in additive manufacturing solutions, and Limbitless Solutions, a nonprofit research facility at the University of Central Florida dedicated to empowering children through bionics, today announced the expansion of a 12-year collaboration that has already helped deliver hundreds of 3D-printed prosthetic devices to children across the United States and beyond. The expanded partnersh

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commerciali

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Wellvii today announced that its innovative BP Go blood pressure monitoring technology achieved FDA clearance, marking a significant milestone in the company’s mission to transform remote patient monitoring and connected healthcare. The BP Go is designed to simplify the blood pressure measurement by utilizing a convenient finger-based measurement approach, eliminating many of the challenges associated with traditional arm cuffs. The device is designed

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un

BOCA RATON, Fla.--(BUSINESS WIRE)-- #HealthcareInnovation--SurGenTec®, a developer of surgical technologies for spine and orthopedic procedures, today announced that it has been named to the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. The prestigious list recognizes companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2

HOLLYWOOD, Fla. & DALLAS--(BUSINESS WIRE)--DermCare Management, LLC (“DermCare”), a leader in specialized dermatology and cosmetic surgery practice-management services, and U.S. Dermatology Partners (“USDP”), a leading dermatology practice, today announced the completion of a strategic transaction that creates one of the largest dermatology groups in the U.S., spanning 12 states. The transaction unites two clinically focused organizations with aligned missions to expand access to high-quality d

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). Thi

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences Announces Positive CRSwNP Results

TAMPA, Fla.--(BUSINESS WIRE)--American Ocean Minerals Corporation ("AOMC" or the "Company") today announced that Paul Warmé has been appointed Chief Financial Officer. Through its previously announced merger with Odyssey Marine Exploration (NASDAQ: OMEX), AOMC is establishing a U.S.-based global supply chain for critical minerals and rare earth elements sourced from deep-sea polymetallic nodules, and Warmé’s appointment further strengthens the executive leadership team as the Company advances t

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. T

CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs and Leaf Health today announced the integration of PriceMDs’ API into LeafIQ, Leaf Health’s pharmacy analytics and reporting platform. The integration enables brokers and third-party administrators to evaluate applicable SourceDirectRx pricing and initiate clinical referrals while analyzing pharmacy spend and specialty medication exposure. Within LeafIQ, users can compare a plan’s current medication cost with available SourceDirectRx pricing without l

GAITHERSBURG, Md.--(BUSINESS WIRE)--Silvec Biologics Inc., a Maryland-based agricultural biotechnology company, is pleased to announce that its novel RNA-based therapy delivery product is now registered for unconditional commercial use under the U.S. Environmental Protection Agency’s (EPA) Federal Insecticide, Fungicide and Rodenticide Act. The product is based on a naturally non-transmitted version of the citrus tristeza virus that is already found in most Florida citrus trees that has been re

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim

JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Space Microgravity Development LLC (SpaceMD), a wholly owned subsidiary of Redwire Corporation (NYSE:RDW) and venture company focused on leveraging the microgravity environment to create dynamic innovations, announced today that it has signed a contract for a Starfall mission. Starfall is SpaceX’s new spacecraft that enables affordable, routine access to a microgravity environment and provides unique opportunities for on-orbit manufacturing, scientific resea

TULSA, Okla.--(BUSINESS WIRE)--Four startups headquartered in Colorado, Florida and Texas have been selected as winners of the 2026 Rose Rock Bridge Showcase. Austere Environmental, BiaTech, BigMachine AI and Intellicess will receive a share of $400,000 in non-dilutive funding and establish a presence in Tulsa to pilot and advance their technologies over the next year. The winning startups were selected from a pool of 85 highly qualified applicants. Collectively, they have already raised over $

MIAMI & NASHVILLE, Tenn.--(BUSINESS WIRE)-- #Oncology--OpenEvidence, the most widely used AI-powered medical search and clinical decision-support platform, and OneOncology, a physician-led national platform empowering independent medical specialty practices, today announced a partnership to embed OpenEvidence into certain clinical applications used across OneOncology’s platform to enable physicians to use OpenEvidence for clinical evidence retrieval, reference and research. The integration is designed to m

NEW YORK & MIAMI--(BUSINESS WIRE)-- #OpenEvidence--Springer Nature and OpenEvidence today announced a subscription agreement that brings peer-reviewed content from Springer Nature into OpenEvidence, where physicians can retrieve and cite it during patient care. This agreement took effect August 4 and forms part of Springer Nature’s community led ARC3 framework. Clinicians and healthcare professionals need quick and easy access to the very latest trusted insights to help inform their decisions. Today's announce

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class investigational bispecific antibody ivonescimab, into urothelial carcinoma, or bladder cancer, with the initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial. Summit is starting a randomized Phase II/III clinical study, HARMONi-GU1, to evaluate ivonescimab plus the antibody-drug co

LAKELAND, Fla.--(BUSINESS WIRE)--Publix’s sales for the three months ended June 27, 2026 were $15.7 billion, a 1% increase from $15.6 billion in 2025. Publix’s sales for the six months ended June 27, 2026 were $31.9 billion, a 1.5% increase from $31.4 billion in 2025. The increase in sales for the three and six months ended June 27, 2026 compared to the three and six months ended June 28, 2025 was lower due to the impact of the Medicare maximum fair price (MFP) change effective January 1, 2026

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #ASPC2026--The Family Heart Foundation, a leading research, education and advocacy organization, today announced that Founder and Chief Executive Officer Katherine Wilemon has been named the 2026 Honorary Fellow Awardee by the American Society for Preventive Cardiology (ASPC), one of the nation's leading professional societies dedicated to advancing cardiovascular disease prevention. The award was presented during the ASPC 2026 Congress on Cardiovascular Disease Pre

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are enc

FORT WORTH, Texas--(BUSINESS WIRE)--EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination

KISSIMMEE, Fla.--(BUSINESS WIRE)-- #BattlefieldMedicine--PVP Labs, a clinical-stage biotechnology company advancing peptide-based therapeutics, today announced that research on Taphalgin® (Lumekefamide) has been selected for oral presentation at the 2026 Military Health System Research Symposium (MHSRS), a premier scientific forum focused on the unique medical needs of deployed Warfighters.Joseph Stauffer, D.O., MBA, FAPCR, Chief Medical Officer of PVP Labs, will present the company's research on Taphalgin as a promis

ORLANDO, Fla.--(BUSINESS WIRE)--Jackson PharmacyPros™, a pharmacy-exclusive staffing agency and workforce solutions provider, has been named to RXinsider's 2026 Pharmacy500, an annual recognition honoring the top pharmacy operations, supply chain businesses and associations that have made a significant impact on dispensing pharmacies across the United States over the past year. The 2026 listmakers are shaping the future of pharmacy through operational excellence, innovation and exceptional pati

LAKELAND, Fla.--(BUSINESS WIRE)--Eligible Medicare Plan D beneficiaries can have qualifying GLP-1 prescriptions filled at a Publix Pharmacy as part of the Medicare GLP-1 Bridge program. On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge program, a new initiative designed to expand access to innovative GLP-1 drugs for weight management. The program will remain available through Dec. 31, 2027. Covered Prescriptions The GLP-1 drugs currently availa

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons

BOCA RATON, Fla. & CHARLOTTE, N.C. & ATLANTA--(BUSINESS WIRE)--Massive Bio, Inc., a leader in AI-enabled oncology clinical trial matching and patient navigation, and QC Healthcare, LLC, a nationwide company focused on telehealth, clinical research, pharmacy services, artificial intelligence, healthcare analytics, and population health, today announced a strategic collaboration to fundamentally reshape how cancer patients access clinical trials, coordinated care, and telehealth support throughou

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.

GAINESVILLE, Fla.--(BUSINESS WIRE)--Kiddom and the University of Florida Lastinger Center announced a research partnership studying if and how embedding professional learning at a teacher's precise point-of-need impacts instruction and student outcomes in middle school math.Kiddom built Florida's B.E.S.T.-aligned math curriculum to give teachers their core instructional materials, assessments, and insights in one coherent system. This partnership goes further, weaving Lastinger Center's instruct

ST. AUGUSTINE, Fla.--(BUSINESS WIRE)-- #MBC--Greenspace Health, a leader in Measurement-Based Care (MBC) technology for behavioral health, has launched Momentum, a new industry publication created to help behavioral health leaders navigate the growing shift toward outcomes-focused, value-based care. Featuring research, real-world case studies and practical implementation strategies, Momentum provides evidence-informed insights into the clinical, operational and economic impact of Measurement-Based Car

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin American Study Group on Lymphoproliferative Disorders (GELL), one of the most influential scientific and academic networks dedicated to lymphomas and hematologic malignancies in Latin America, today announced a strategic partnership focused on advancing clinical research, physician education, and innovation throu

PENSACOLA, Fla.--(BUSINESS WIRE)--Sugar Sands Publishing LLC today announced the formal constitution of the independent Cognitive Mode Operating System Standards Board (CMOS-SB) and launch of a governance framework for how AI systems interact with human emotion and cognition. THE GOVERNANCE GAP AI systems are increasingly being used in enterprise, health care, education and public infrastructure, where they can read emotional cues, respond to cognitive patterns and influence how people relate t

BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-L™ navigation instruments for use with the ION-L™ Lumbar Facet Fixation System. The system is engineered for compatibility with Medtronic's StealthStation™ navigation platform, enabling enhanced precision during posterior lumbar facet fusion proced

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf

TAMPA, Fla.--(BUSINESS WIRE)-- #biotech--Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs. Founded on breakthrough discoveries published today in Science by scientists at Moffitt Cancer Center, the company is advancing an integrated platform that combines novel covalent chemistry with AI-enabled chemoproteomics to unlock a new generatio

MIAMI & LOS ANGELES--(BUSINESS WIRE)-- #ClinicalAI--The Los Angeles County Department of Public Health (DPH) and OpenEvidence, an AI-powered clinical decision support platform, today announced a collaboration to help physicians quickly find official LA County Public Health resources when searching for clinical information. Under this new partnership, when physicians in LA County search the platform for selected public health topics, OpenEvidence will display related LA-specific messages from Public Health. T

BOCA GRANDE, Fla.--(BUSINESS WIRE)--Avanti Capital establishes The Foundation in the U.S., advancing a multigenerational philanthropic legacy focused on research, education and impact.

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne

MIAMI--(BUSINESS WIRE)--ReturnPro, the industry leader in returns management and reverse logistics, today announced findings from its new consumer study examining the effects of GLP-1 medications and how they are quietly reshaping what consumers are buying, returning, holding onto and wishing retailers would do differently to address their unique needs. The GLP-1 Effect report surveyed 500 U.S. adults currently taking, or who have taken within the past 12 months, a GLP-1 medication (Ozempic, We

JUPITER, Fla.--(BUSINESS WIRE)--Cancer Cell Diagnostics today announced the commercial launch of its CellSight™ DNA comprehensive genomic profiling test. This test is built on a fundamentally distinct source material from conventional liquid biopsy. Most blood-based cancer tests analyze cell-free circulating tumor DNA, the short, degraded fragments that tumors shed into the bloodstream. CCDx utilizes a different approach. The CellSight™ platform uses a proprietary, patent-pending enrichment met

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive’s portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. Building on the existing indication for I

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi

TORONTO--(BUSINESS WIRE)-- #ARDS--Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health System Research Symposium (MHSRS), DOW's premier scientific meeting

JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, has opened its new 30,000 square foot state-of-the-art, vertically-integrated research and microgravity payload development facility in Georgetown, Indiana. The facility will serve as a global hub supporting accelerated demand as the company continues to expand its leadership in space-enabled research, development, and manufacturing with a focus on pharmaceutical/biot

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio partners with FOMAT, the largest U.S. Embedded Research Organization, to launch AI-powered cancer patient prescreening for clinical trials

MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon expands its seating line with Verro, a Medicare-coded custom cushion engineered for wheelchair users with complex postural needs.

MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will present at the Society of Robotic Surgery (SRS) Annual Meeting in Hollywood, Florida, July 22–26, 2026, on booth #325. At the meeting, interventional radiology leaders Prof. Dr. Sean Tutton, MD, Professor of Radiology and Orthopedics, and Dr. Govindarajan Narayanan, MD, FSIR, Professor of Radiology and Chief of Interventional Oncology and the first physician to treat a patient with Epion

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdomi

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, announced today the featured innovations in quality assurance (QA) for machine oversight and adaptive radiotherapy, as well as AI-assisted treatment planning, to be shown at the 2026 AAPM & COMP Annual Meeting, July 19–21 in Vancouver. Centered on the theme of Next-Gen Innovations for Next-Level Physics, the Sun Nuclear exhibit reflects a focus on smart, practical tools that support medical physics teams to operate wit